TNGX Q3 2022 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+2.0% YoY

Gross Profit

$6M82.4% margin

Operating Income

-$30M-432.4% margin

Net Income

-$29M-419.8% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

+19.9%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$23M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$464M

Total Liabilities

$191M

Stockholders' Equity

$273M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$7M	+2.0%
Gross Profit	$6M	-$15M	+137.7%
Operating Income	-$30M	-$20M	-52.9%
Net Income	-$29M	-$20M	-48.3%

Revenue Segments

Collaboration Revenue

$7M100%